Loading
Children started surviving cancer in the 1960s, and within a decade the doctors who had cured them began writing down what the cure had cost. The phrase that stuck, from a 1975 paper by Giulio D'Angio, is that cure is not enough.
Recovery became a research subject because paediatric oncology succeeded first. Combination chemotherapy and radiotherapy turned childhood leukaemia and several childhood solid tumours from almost always fatal into often curable within about fifteen years, and the children who were cured then grew up. In 1975 Giulio D'Angio published a short paper in Cancer under the title "Pediatric cancer in perspective: cure is not enough". The title is the argument. A field that measures itself only by whether the patient is alive at five years will not notice a thirty-year-old with heart failure, a second cancer, no fertility and no final-year schooling, because none of those things appears in its denominator.
For about twenty years the evidence was case series from single hospitals, which is enough to raise an alarm and not enough to tell a family what their own risk is. The change came with cohorts. The Childhood Cancer Survivor Study, established in 1994 as a consortium of twenty-five North American institutions, assembled 20,276 eligible five-year survivors diagnosed before the age of 21 between 1970 and 1986, of whom 14,054 completed a 24-page baseline questionnaire, with medical records abstracted for chemotherapy, radiotherapy and surgery in 98 per cent of participants. That abstraction is the part that matters: it is what lets a late effect be tied to a specific drug at a specific cumulative dose rather than to "having had cancer".
The cohort's best-known result, published in 2006, is that 62.3 per cent of adult survivors of childhood cancer had at least one chronic health condition and 27.5 per cent had a severe or life-threatening one, against their own siblings as the comparison group. In 2013 the St Jude Lifetime Cohort went further by examining survivors clinically rather than asking them, and found a far higher burden than questionnaires had shown, which established that self-report understates the problem.
From the cohorts came guidelines. The Children's Oncology Group Long-Term Follow-Up Guidelines, first described in 2004, are risk-based: they key surveillance to the exposure a survivor actually had rather than to the diagnosis they were given, which is why a treatment summary is the precondition for using them at all. The International Guideline Harmonization Group now reconciles the American, British and European versions so that a survivor who moves country is not given three different answers.
What changed, concretely, is that late effects moved from being an unfortunate footnote to being a design constraint on treatment. Trials now de-escalate: less radiotherapy, lower cumulative anthracycline, alkylator-free options where an equivalent exists. The paediatric late-mortality record on this front holds the evidence that this worked. What has not changed is that the same arithmetic was never done for adults with anything like the same rigour, which is the gap named on `rejuv-agenda-late-effects-are-not-counted`.
Shares British Childhood Cancer Survivor Study (BCCSS), Registries count diagnoses and deaths, and not what treatment left behind, St Jude Lifetime Cohort Study (SJLIFE), International Guideline Harmonization Group for late effects of childhood cancer and the tags rejuvenation, survivorship, late-effects, paediatric.
Shares St Jude Lifetime Cohort Study (SJLIFE), International Guideline Harmonization Group for late effects of childhood cancer, The Children's Oncology Group Long-Term Follow-Up Guidelines, How much illness childhood cancer survivors carry, and at what age and the tags rejuvenation, survivorship, late-effects, paediatric.
Shares Late deaths after childhood cancer, what causes them, and the proof that gentler treatment worked, St Jude Lifetime Cohort Study (SJLIFE), International Guideline Harmonization Group for late effects of childhood cancer, The Children's Oncology Group Long-Term Follow-Up Guidelines and the tags rejuvenation, survivorship, late-effects, paediatric.
Shares Late deaths after childhood cancer, what causes them, and the proof that gentler treatment worked, St Jude Lifetime Cohort Study (SJLIFE), International Guideline Harmonization Group for late effects of childhood cancer, The Children's Oncology Group Long-Term Follow-Up Guidelines and the tags rejuvenation, survivorship, late-effects, paediatric.
Shares St Jude Lifetime Cohort Study (SJLIFE), International Guideline Harmonization Group for late effects of childhood cancer, The Children's Oncology Group Long-Term Follow-Up Guidelines, How much illness childhood cancer survivors carry, and at what age and the tags rejuvenation, survivorship, late-effects, paediatric.
Shares St Jude Lifetime Cohort Study (SJLIFE), International Guideline Harmonization Group for late effects of childhood cancer, The Children's Oncology Group Long-Term Follow-Up Guidelines, How much illness childhood cancer survivors carry, and at what age and the tags rejuvenation, survivorship, late-effects, paediatric.
Shares St Jude Lifetime Cohort Study (SJLIFE), International Guideline Harmonization Group for late effects of childhood cancer, The Children's Oncology Group Long-Term Follow-Up Guidelines, How much illness childhood cancer survivors carry, and at what age and the tags rejuvenation, survivorship, late-effects, paediatric.
Shares St Jude Lifetime Cohort Study (SJLIFE), International Guideline Harmonization Group for late effects of childhood cancer, The Children's Oncology Group Long-Term Follow-Up Guidelines, How much illness childhood cancer survivors carry, and at what age and the tags rejuvenation, survivorship, late-effects, paediatric.